Inspyr Therapeutics Initiates Mipsagargin with Nexavar® Combination Therapy Programs for Liver Cancer
January 03, 2017 07:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of...
UPDATE -- Inspyr Announces Private Placement of $1.0 Million
December 12, 2016 09:50 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD) (“Inspyr” or the “Company”), a biotech company developing novel prodrug therapeutics for the treatment...
Inspyr Announces Private Placement of $1.0 Million
December 12, 2016 07:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX) (“Inspyr” or the “Company”), a biotech company developing novel prodrug therapeutics for the treatment of...
Inspyr Broadens Intellectual Property Portfolio with New Patent Issued on Methods for Producing Cancer Compounds
October 20, 2016 07:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced...
Inspyr Therapeutics Appoints Richard Buller, M.D., Ph.D. to Board of Directors
October 13, 2016 07:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced...
Inspyr Therapeutics Appoints Claire Thom, Pharm.D. to Board of Directors
October 12, 2016 07:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced...
Inspyr Therapeutics Strengthens Clinical Development Capabilities with Appointment of Michael Elliott as Vice President of Clinical Operations
October 11, 2016 07:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced...